CALCIMEDICA INC (CALC)
US38942Q2021 - Common Stock
CALC Stock Earnings: CalciMedica Reported Results for Q4 2023
CalciMedica just reported results for the fourth quarter of 2023.
CALC Stock Earnings: CalciMedica Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CalciMedica (NASDAQ:CALC) just reported results for the fourth quarter of 2023....
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024 Auxora granted Investigational New...
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
/PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
CalciMedica files to sell 10.74M shares for holders (NASDAQ:CALC)
CalciMedica files prospectus, offering to resale 10.74 million common shares.
CalciMedica to raise up to ~$55M (NASDAQ:CALC)
CalciMedica is set to raise $55M through a private placement, with funds from new and existing investors.
CalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition
Treatment with Auxora™ shown to potentially reduce the severity of asparaginase-associated pancreatitis, also called asparaginase-induced pancreatic toxicity,...
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
CalciMedia CEO discloses purchase of 2K shares (NASDAQ:CALC)
CalciMedia (CALC) CEO Rachel Leheny disclosed the purchase of 2,440 shares of the company at a transaction value of $7,615. Filing More on CalciMedica Historica
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
CalciMedica Announces Upcoming Presentations and Events in September
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CARPO top-line data expected in 1H2024 CARPO enrolling in over 30 sites in the US and India LA JOLLA, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) --...
CalciMedica Announces Relisting on Nasdaq
CalciMedica Announces Relisting on Nasdaq
LA JOLLA, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on...
CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)
Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP Data show...
CalciMedica Expands Executive Team with New Appointments
Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development
CalciMedica Expands Executive Team with New Appointments
Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development...
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on...